FDA assigns Fast Track Designation to Desmoglein 3 Chimeric AutoAntibody Receptor T cells (DSG3-CAART) for treatment of mucosal pemphigus vulgaris (mPV)

DSG3-CAART is designed to specifically target the cause of mPV, B cells that express pathogenic autoantibodies directed against the DSG3 protein, while preserving normal B cell immune function, with aim of improving healing of mucosal blisters. A Phase 1 study is planned for 2020


Biospace Inc.